OBJECTIVE	Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized , placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease .\